Choline for Cognitive Function

Verdict: Weak, population-specific cognitive evidence

Choline is an essential nutrient for normal brain function, but supplementing it does not reliably improve cognition in healthy, well-nourished adults. The limited benefits seen in trials come from choline derivatives in people who are already cognitively impaired or aging, not from plain choline as a brain booster.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

This earns a weak (C) grade because the human trials that show benefit are narrow and do not test what most consumers buy. The two positive randomized trials used choline derivatives, not plain choline: a 12-week trial of alpha-GPC in amnestic mild cognitive impairment (PMID 39300341, ADAS-cog improved by ~2.3 points) and a citicoline trial in older adults with age-associated memory impairment (PMID 33978188). A small, industry-funded alfoscerate trial in type 2 diabetes (PMID 39703111, n=36) was very low quality.

Crucially, the signals appear only in impaired or aging populations, and no clear benefit has been shown for choline-replete healthy adults. The strongest meta-analytic data (PMID 36041182, n=5570) is observational and concerns maternal choline and fetal brain development, not adult cognitive enhancement. Two of three RCTs were industry-funded, which the engine flags as a funding-bias concern.

Regulators and clinics reinforce the caution. The FDA treats choline only as a nutrient supplement with no approved cognitive health claim, EFSA formally rejected claims for normal cognitive function and brain development, and NIH and Harvard note trials have not shown cognitive benefit. Mayo Clinic frames choline as a dietary essential rather than a high-dose enhancer, leaving the overall clinical picture mixed.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.51
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
66%
Broadly consistent
Evidence level
E3
Single high-quality meta-analysis

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.38
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
L2 PubMedPrimary literature
0.60
L3 MechanismPlausibility
0.65
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.511
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Association between Maternal Choline, Fetal Brain Development, and Child Neurocognition: Systematic Review and Meta-Analysis of Human Studies
PMID: 36041182 2022 系統性回顧 n = 5,570
Finding: Low maternal choline associated with higher NTD risk (pooled OR 1.36); higher intake observationally favorable for child neurocognition.
Academic Effect size: OR 1.36 (95% CI 1.11-1.67)
View on PubMed
Efficacy and safety of choline alphoscerate for amnestic mild cognitive impairment: a randomized double-blind placebo-controlled trial
PMID: 39300341 2024 RCT (double-blind) n = 100
Finding: alpha-GPC group showed ADAS-cog decrease of 2.34 points, significantly greater than placebo.
Effect size: MD ~2.34 points ADAS-cog
View on PubMed
Effects of choline alfoscerate on cognitive function and quality of life in type 2 diabetes: A double-blind, randomized, placebo-controlled trial
PMID: 39703111 2025 RCT (double-blind) n = 36
Finding: MMSE improved by mean +1.7 vs placebo at 12 months (p < 0.001); small sample.
🟠 Limited quality ⚠️ Industry-funded Effect size: MD +1.7 MMSE points
View on PubMed
Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
PMID: 33978188 2021 RCT (double-blind) n = 100
Finding: Citicoline improved episodic memory (0.15 vs 0.06, p=0.0025) and composite memory (3.78 vs 0.72, p=0.0052) in healthy older adults with age-associated memory impairment.
⚠️ Industry-funded Effect size: episodic memory MD 0.09; composite MD 3.06
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Supportive
NUTRIENT SUPPLEMENT source↗
L4d TW TFDA / 衛福部
Supportive
成年男性膽鹼建議攝取量每日至少450毫克、女性每日至少390毫克,孕婦則應提高至每日410毫克以上;膽鹼補充上限為每日3.5公克。膽鹼為「國人膳食營養素參考攝取量」第八版新增的營養素。 source↗
L4e WHO
Supportive
Codex Standard for Infant Formula (CXS 72-1981): minimum choline content 7 mg/100 kcal, maximum 50 mg/100 kcal (1.7 mg/100 kJ minimum, 12 mg/100 kJ maximum). source↗
L5b Mayo Clinic
Cautious
choline plays a role in memory, mood, and how our muscles and nervous system work by producing certain neurotransmitters source↗
L5e Specialty Society (condition-mapped)
Against
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-cognitive-function-INT-choline-001 繁體中文版 →